NAC441A.200. List of adopted recommendations, guidelines and publications; review of revision or amendment of adopted recommendation, guideline or publication.

     1. The following recommendations, guidelines and publications are adopted by reference:

     (a) The standard precautions to prevent transmission of disease by contact with blood or other body fluids as recommended by the Centers for Disease Control and Prevention in “Perspectives in Disease Prevention and Health Promotion Update: Universal Precautions for Prevention of Transmission of Human Immunodeficiency Virus, Hepatitis B Virus, and Other Bloodborne Pathogens in Health-Care Settings,” Morbidity and Mortality Weekly Report [37(24):377-388, June 24, 1988], published by the United States Department of Health and Human Services and available at no cost on the Internet at http://www.cdc.gov/mmwr/.

     (b) The Centers for Disease Control and Prevention’s 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings, published by the United States Department of Health and Human Services and available at no cost on the Internet at http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/Isolation2007.pdf.

     (c) The recommended guidelines for the investigation, prevention, suppression and control of communicable disease set forth by the Centers for Disease Control and Prevention in:

          (1) “General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices,” Morbidity and Mortality Weekly Report [55(RR15):1-48, December 1, 2006], published by the United States Department of Health and Human Services and available at no cost on the Internet at http://www.cdc.gov/mmwr/; and

          (2) Manual for the Surveillance of Vaccine-Preventable Diseases, 4th edition, published by the United States Department of Health and Human Services and available at no cost on the Internet at http://www.cdc.gov/vaccines/pubs/surv-manual/.

     (d) The recommended guidelines for the investigation, prevention, suppression and control of communicable diseases contained in Control of Communicable Diseases Manual, 19th edition, published by the American Public Health Association and available for the price of $25 for members and $35 for nonmembers from the American Public Health Association, 800 I Street, N.W., Washington, D.C. 20001-3710, or at the Internet address http://www.apha.org.

     (e) The recommended guidelines for the investigation, prevention, suppression and control of communicable diseases contained in Red Book: 2009 Report of the Committee on Infectious Diseases, 28th edition, published by the American Academy of Pediatrics and available for the price of $99.95 for members and $114.95 for nonmembers from the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois 60007, or at the Internet address http://www.aap.org.

     (f) The recommendations for the testing, treatment, prevention, suppression and control of chancroid, Chlamydia trachomatis, gonococcal infection, granuloma inguinale, lymphogranuloma venereum and infectious syphilis as are specified in “Sexually Transmitted Diseases Treatment Guidelines, 2006,” Morbidity and Mortality Weekly Report [55(RR11):1-94, August 4, 2006], published by the United States Department of Health and Human Services and available at no cost on the Internet at http://www.cdc.gov/mmwr/.

     (g) The recommendations for the counseling of and effective treatment for a person having active tuberculosis or tuberculosis infection as set forth in:

          (1) “Controlling Tuberculosis in the United States: Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America,” Morbidity and Mortality Weekly Report [54(RR12):1-81, November 4, 2005], published by the United States Department of Health and Human Services and available at no cost on the Internet at http://www.cdc.gov/mmwr/;

          (2) “Treatment of Tuberculosis,” Morbidity and Mortality Weekly Report [52(RR11):1-77, June 20, 2003], published by the United States Department of Health and Human Services and available at no cost on the Internet at http://www.cdc.gov/mmwr/; and

          (3) “Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection,” Morbidity and Mortality Weekly Report [49(RR06):1-54, June 9, 2000], published by the United States Department of Health and Human Services and available at no cost on the Internet at http://www.cdc.gov/mmwr/.

     (h) The recommendations of the Centers for Disease Control and Prevention for preventing the transmission of tuberculosis in facilities providing health care set forth in “Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Settings, 2005,” Morbidity and Mortality Weekly Report [54(RR17):1-141, December 30, 2005], published by the United States Department of Health and Human Services and available at no cost on the Internet at http://www.cdc.gov/mmwr.

     (i) “Case Definitions for Infectious Conditions Under Public Health Surveillance,” Morbidity and Mortality Weekly Report [46(RR10):1-55, May 2, 1997], published by the United States Department of Health and Human Services and available at no cost on the Internet at http://www.cdc.gov/mmwr/.

     (j) “Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines,” Morbidity and Mortality Weekly Report [54(RR14):1-16, December 9, 2005], published by the United States Department of Health and Human Services and available at no cost on the Internet at http://www.cdc.gov/mmwr/.

     (k) “Updated Recommendations for Isolation of Persons with Mumps,” Morbidity and Mortality Weekly Report [57(40):1103-1105, October 10, 2008], published by the United States Department of Health and Human Services and available at no cost on the Internet at http://www.cdc.gov/mmwr/.

     (l) “Recommendations for Partner Services Programs for HIV Infection, Syphilis, Gonorrhea, and Chlamydial Infection,” Morbidity and Mortality Weekly Report [57(RR09):1-83, November 7, 2008], published by the United States Department of Health and Human Services and available at no cost on the Internet at http://www.cdc.gov/mmwr/.

     2. Within 90 days after the publication of a revision of a recommendation, guideline or publication adopted by reference pursuant to subsection 1, the Board may make a determination of its suitability for this State. In making its determination, the Board will consider the recommendation submitted by the State Health Officer pursuant to subsection 5. If the Board determines that a revision is not suitable for this State, the Board will:

     (a) Hold a public hearing to reconsider its determination within 90 days after the date of publication of the revision; and

     (b) Give notice of that hearing.

     3. If, after a hearing held pursuant to subsection 2, the Board does not revise its determination, the Board will give notice within 30 days after the hearing that the revision is not suitable for this State.

     4. A revision of a recommendation, guideline or publication adopted by reference pursuant to subsection 1 becomes part of the recommendation, guideline or publication:

     (a) Immediately upon a determination by the Board that the revision is suitable for this State;

     (b) Immediately upon the conclusion of a hearing held pursuant to subsection 2 if the Board revises its determination and decides that the revision is suitable for this State; or

     (c) Ninety days after the date of publication of the revision if the Board does not make a determination concerning suitability for this State.

     5. The State Health Officer or his or her designee shall review each revision of a recommendation, guideline or publication adopted by reference pursuant to subsection 1 to recommend whether the revision is appropriate for application in this State and shall submit the recommendation to the Board for its review at the next regularly scheduled meeting of the Board following the publication of the revision.

     (Added to NAC by Bd. of Health, eff. 1-24-92; A by R047-99, 9-27-99; R084-06, 7-14-2006; R087-08, 1-13-2011)